Purpose: Pfizer’s purpose is breakthroughs that change patients' lives.
At its heart, Pfizer is a science-based company that is working to deliver on scientific breakthroughs by translating a deep understanding of biology into potentially transformative therapies in areas where it has been thought there is no hope for patients.
Pfizer is focused on preventing disease, driving remission and ultimately finding cures. Pfizer is harnessing its scientific capabilities, talent and collaborations to advance new modalities with the potential of addressing unmet patient needs in several therapeutic areas: Oncology, Rare Disease, Inflammation and Immunology, Internal Medicine, and Vaccines.
Pfizer is one of the largest investors in R&D with a 2018 R&D investment of $8 billion. Pfizer’s talented scientists and clinicians have deep scientific insights and expertise that build on Pfizer’s strengths, such as its world-class small molecule platform, end-to-end biologics and vaccines capabilities.
Across Pfizer’s areas of research, it is investigating vaccines for deadly infections such as C. difficile, Respiratory Syncytial Virus, Pneumococcal Pneumonia, and Group B Strep. Pfizer is also advancing the next wave of innovation in cancer research with a portfolio of targeted therapies and immuno-oncology (IO), looking at both monotherapies and combinations. In immunoinflammatory diseases, Pfizer is investigating potential new therapies for atopic dermatitis, alopecia areata, IBD, vitiligo, and Crohn’s disease, with an array of kinase inhibitors. It is seizing opportunities in gene therapy to find potential cures for diseases like hemophilia A and B, and Duchenne muscular dystrophy. In Internal Medicine, Pfizer is advancing potential options for patients living with Nonalcoholic Steatohepatitis, or NASH.
To ensure that it is advancing the best science, Pfizer’s R&D organization is working on early discovery to development, while also exploring external opportunities. Pfizer’s widespread collaborations span the entire ecosystem – partnering with academia, medical centers, government, patients, venture capital and others – to help shape the health innovation environment. Its core R&D sites are in Cambridge, MA, Groton, CT, La Jolla, CA, St. Louis, MO and the North Carolina Research Triangle, where Pfizer works closely with collaborators clustered in these hubs of scientific excellence.
“Pfizer is actively supporting the development of an emerging, highly-networked ecosystem that will catalyze tomorrow’s scientific and medical innovations. In this journey, we hope to advance unique models of collaboration with creativity, flexibility and openness to deliver innovation quickly, regardless of where the talent and resources reside,” says Mikael Dolsten, MD, PhD, Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer.